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BACKGROUND: Atrial fibrillation (AF) is a major risk factor for mortality. The prevalence, clinical correlates, and prognostic impact 
of AF in Takotsubo syndrome (TTS) have not yet been investigated in a large patient cohort. This study aimed to investigate 
the prevalence, clinical correlates, and prognostic impact of AF in patients with TTS.
METHODS AND RESULTS: Patients with TTS were enrolled from the International Takotsubo Registry, which is a multinational 
network with 26 participating centers in Europe and the United States. Patients were dichotomized according to the presence 
or absence of AF at the time of admission. Of 1584 patients with TTS, 112 (7.1%) had AF. The mean age was higher (P<0.001), 
and there were fewer women (P=0.046) in the AF than in the non- AF group. Left ventricular ejection fraction was significantly 
lower (P=0.001), and cardiogenic shock was more often observed (P<0.001) in the AF group. Both in- hospital (P<0.001) 
and long- term mortality (P<0.001) were higher in the AF group. Multivariable Cox regression analysis revealed that AF was 
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independently associated with higher long- term mortality (hazard ratio, 2.31; 95% CI, 1.50– 3.55; P<0.001). Among patients 
with AF on admission, 42% had no known history of AF before the acute TTS event, and such patients had comparable in- 
hospital and long- term outcomes compared with those with a history of AF.
CONCLUSIONS: In patients presenting with TTS, AF on admission is significantly associated with increased in- hospital and 
long- term mortality rates. Whether antiarrhythmics and/or cardioversion are beneficial in TTS with AF should thus be tested 
in a future trial.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT01947621.
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Takotsubo syndrome (TTS) is characterized by acute left ventricular (LV) dysfunction.1 This syn-drome has historically been considered a benign 
disease, as the LV dysfunction recovers spontaneously 
within a few weeks.2 However, recent data show that 
TTS is associated with a substantial risk of adverse 
events both during the acute phase and in the long- 
term, with complication rates comparable with those of 
acute coronary syndrome (ACS).3,4 The occurrence of 
complications in patients with TTS is associated with 
poor and even fatal outcomes. For example, patients 
with TTS can experience concurrent arrhythmias, se-
vere heart failure with or without pulmonary edema, 
cardiogenic shock, and LV free- wall rupture.5 A recent 
international consensus document on TTS reported 
that cardiac arrhythmias are a major determinant of 
clinical outcomes in patients with TTS.5
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia, and its presence has been asso-
ciated with a 5- fold increase in the incidence of stroke 
and a 2- fold increase in mortality.6,7 AF among patients 
with TTS has been reported in several small studies, 
with a prevalence ranging from 5% to 25%.8,9 Recent 
evidence suggested that patients with TTS with AF, 
including those with newly diagnosed AF at the time 
of TTS presentation, may have worse short- term and 
long- term mortality rates compared with those without 
AF.10,11 However, the impact of a history of AF versus 
newly diagnosed AF in the context of an acute event 
has not been evaluated in a large cohort. To overcome 
this drawback, we analyzed data from the International 
Takotsubo Registry (InterTAK Registry), which is the 
largest available cohort of patients with TTS, to deter-
mine the prevalence, clinical correlates, and prognos-
tic impact of AF in patients with TTS.
METHODS
Study Population
The study design of the InterTAK Registry has been 
comprehensively outlined previously.3 The inclusion 
criteria were the Mayo Clinic Diagnostic Criteria:12 
(1) transient LV wall motion abnormalities beyond a 
single epicardial coronary artery distribution territory; 
(2) absence of obstructive coronary artery disease or 
acute plaque rupture, which could explain the wall 
motion abnormalities; (3) evidence of new ECG ab-
normalities and/or elevation in cardiac troponin lev-
els; and (4) absence of myocarditis. Exceptions to 
these criteria were3 patients who matched all other 
criteria but had wall motion abnormalities corre-
sponding to the territory of a single coronary artery 
as well as those who died during the acute phase, 
before complete LV wall motion recovery. The au-




• The prevalence of atrial fibrillation (AF) on ad-
mission in patients with takotsubo syndrome 
(TTS) was 7%, and patients with TTS with AF 
on admission had more eventful in- hospital 
courses and significantly higher mortality rates 
compared with those without AF.
• 42% of patients with TTS had no known history 
of AF before their TTS index event, suggesting 
that these patients may have developed new- 
onset AF.
• Patients with TTS with preexisting AF and newly 
diagnosed AF had comparable in- hospital and 
long- term outcomes.
What Are the Clinical Implications?
• The presence of AF in TTS should alert clinicians 
to the prognostic implications of this rhythm.
Nonstandard Abbreviations and Acronyms
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Data Collection
Data on the patients’ clinical characteristics were 
collected through a review of their medical records 
and included demographics, cardiovascular risk fac-
tors, comorbidities, triggering factors, symptoms at 
admission, laboratory profiles, ECG findings, imag-
ing features, and management. Outcome data were 
collected from clinical visits, personal telephone in-
terviews, or medical charts. AF was diagnosed based 
on guidelines of the European Society of Cardiology, 
which define AF as irregular RR intervals with no dis-
cernable, distinct P waves on admission ECG.13 Atrial 
flutter was considered equivalent to AF. Patients were 
dichotomized according to the presence or absence 
of AF as assessed using 12- lead surface ECG on 
admission, and we compared clinical characteristics 
and in- hospital and long- term outcomes between 
the 2 groups. Furthermore, in a subanalysis, patients 
with AF on admission were categorized into 2 groups 
based on the presence or absence of known history 
of AF before TTS events, and baseline features and 
outcomes were compared. Patients without complete 
information for this categorization were excluded from 
this subanalysis.
The study protocol was reviewed by the local eth-
ics committee or investigational review board at each 
collaborating site. Because of the partly retrospective 
nature of the study, the ethics committees of most 
study centers waived the need for informed consent. 
At centers in which the ethics committees or investi-
gational review boards required informed consent or 
in which patients were included prospectively, formal 
written consent was obtained from the patients or their 
surrogates.
Statistical Analysis
Categorical variables are presented as frequencies 
(percentages), and continuous parameters are ex-
pressed as mean±standard deviation (SD) or as me-
dian (interquartile range [IQR]). Group comparisons 
were conducted using the chi- square test or Fisher 
exact test for categorical variables, and the Student t 
test or Mann– Whitney U test for continuous variables. 
The Kaplan– Meier method was used to assess the 
long- term mortality and major adverse cardiac and 
cerebrovascular event (a composite of a recurrence of 
TTS, myocardial infarction, stroke or transient ischemic 
attack, or death from any cause) rates, and the log- 
rank test was used to compare Kaplan– Meier curves 
as well as a landmark analysis with a landmark set at 
60  days. Cox regression analysis was conducted to 
determine the hazard ratio and 95% CI of AF on admis-
sion for long- term outcomes. To account for possible 
differences in clinical characteristics and comorbidities 
between patients with and without AF, a multivariable 
adjustment analysis including covariates that had a 
significant difference in the baseline comparison was 
performed in a Cox regression model. The number of 
covariates was limited to 12 because of the number of 
events in the study cohort.14 Multiple imputations be-
fore multivariable Cox regression were used to com-
plete missing data. Overall, data on covariates were 
95.6% complete. All tests were 2- sided, and P<0.05 
indicated statistical significance. Statistical analy-
ses were performed using SPSS version 25.0, and 
GraphPad version 7.0 was used for figure preparation.
RESULTS
Patient Characteristics
Of a total of 1750 potentially eligible patients, 1584 
patients with TTS with complete information on AF 
on admission were enrolled in the present study. 
Among these, 112 (7.1%) had AF on admission 
as determined by ECG. Median length of hospi-
talization was 6  days (interquartile range [IQR], 
3– 10  days) in the no AF cohort and 7  days (IQR, 
4– 13 days) in the cohort with AF. Compared with pa-
tients with TTS without AF, those with AF were less 
frequently women (84.8% versus 90.6%; P=0.046) 
and were significantly older (73.8±12.2  years ver-
sus 66.1±13.0  years; P<0.001). Physical trigger-
ing factors were more common among those with 
AF than among those without AF (44.6% versus 
33.8%; P=0.020). A detailed description of trig-
gering factors in patients with and without AF is 
shown in Figure S1. Notably, patients with AF more 
often had the apical TTS type (89.3% versus 81.4%; 
P=0.036), presented with significantly higher levels 
of B- type natriuretic peptide, and had a lower LV 
ejection fraction (37.2±11.1% versus 41.3±11.8%; 
P=0.001) than patients without AF. In addition, C- 
reactive protein level and white blood cell (WBC) 
counts on admission were higher in patients with 
TTS with AF than in patients with TTS without AF 
(Table 1). Preexisting comorbidities such as hyper-
tension (86.1% versus 63.9%; P<0.001), diabetes 
mellitus (25.7% versus 13.0%; P<0.001), and coro-
nary artery disease (22.4% versus 15.2%; P=0.049) 
were more common among those with AF than 
among those without AF. Angiotensin- converting 
enzyme inhibitors/angiotensin receptor blockers 
(52.2% versus 37.3%, P=0.005) and β- blockers 
(48.9% versus 31.6%, P=0.001) had been more fre-
quently prescribed to patients with AF before ad-
mission (Table 1).
In- Hospital Management and Outcomes
Acute cardiac care measures such as intra- aortic 
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cardiopulmonary resuscitation (19.8% versus 7.3%; 
P<0.001), invasive or noninvasive ventilation (27.0% 
versus 14.9%; P=0.001), or catecholamine adminis-
tration (20.7% versus 10.8%; P=0.002) were more 
often required in patients with AF than in patients 
without AF in relation to a significantly higher inci-
dence of cardiogenic shock (20.0% versus 8.8%; 
P<0.001; Table  1). Moreover, in- hospital mortality 
Table 1. Characteristics of TTS Patients with and without 
Atrial Fibrillation






Female sex, no./total 
no. (%)
95/112 (84.8) 1334/1472 
(90.6)
0.046





Takotsubo Type, no./total no. (%)
Apical 100/112 (89.3) 1198/1472 
(81.4)
0.036
Triggers, no./total no. (%)
Physical trigger 50/112 (44.6) 498/1472 (33.8) 0.020
Emotional trigger 25/112 (22.3) 430/1472 (29.2) 0.12
Symptoms on admission, no./total no. (%)
Chest pain 71/100 (71.0) 1061/1381 
(76.8)
0.19
Syncope 5/103 (4.9) 104/1374 (7.6) 0.31
Cardiac biomarkers on admission, median (IQR)
Troponin, factor 
increase in ULN*





Creatine kinase, factor 
increase in ULN
0.82 (0.45– 1.69) 
N=79
0.86 (0.54– 1.46) 
N=1033
0.58







Inflammatory markers on admission, median (IQR)










ECG on admission, no./total no. (%)
ST- segment elevation 50/112 (44.6) 640/1466 (43.7) 0.84
T- wave inversion 43/112 (38.4) 605/1466 (41.3) 0.55




















77.6±17.9 (N=92) 76.6±16.9 
(N=1232)
0.60
Left ventricular ejection 
fraction, %‡
37.2±11.1 (N=101) 41.3±11.8 
(N=1360)
0.001
Left ventricular end- 
diastolic pressure, 
mm Hg
21.5±7.6 (N=66) 21.5±7.9 
(N=890)
>0.99
Cardiovascular risk factors/history, no./total no. (%)
Hypertension 93/108 (86.1) 918/1437 (63.9) <0.001
Diabetes mellitus 28/109 (25.7) 187/1436 (13.0) <0.001
Current smoking 13/104 (12.5) 278/1402 (19.8) 0.07
Hypercholesterolemia 34/108 (31.5) 450/1431 (31.4) 0.99
 (Continued)





Coexisting medical condition, no./total no. (%)
Coronary artery 
disease§
24/107 (22.4) 207/1359 (15.2) 0.049
Cancer (total) 17/99 (17.2) 227/1360 (16.7) 0.90
COPD or asthma 9/105 (8.6) 234/1415 (16.5) 0.032
Hyperthyroidism 8/106 (7.5) 84/1426 (5.9) 0.45
Hypothyroidism 10/106 (9.4) 169/1426 (11.9) 0.46
Medication on admission, no./total no. (%)
ACE inhibitor or ARB 48/92 (52.2) 448/1200 (37.3) 0.005
Beta- blocker 45/92 (48.9) 379/1200 (31.6) 0.001
Statin 16/90 (17.8) 212/1169 (18.1) 0.90
Aspirin 36/90 (40.0) 399/1169 (34.1) 0.26
Vitamin K antagonist 21/90 (23.3) 33/1169 (2.8) <0.001
Acute cardiac care, no./total no. (%)
Intra- aortic balloon 
pump
7/111 (6.3) 34/1466 (2.3) 0.011
Cardiopulmonary 
resuscitation
22/111 (19.8) 107/1466 (7.3) <0.001
Invasive or noninvasive 
ventilation
30/111 (27.0) 218/1466 (14.9) 0.001
Catecholamine use 23/111 (20.7) 158/1466 (10.8) 0.002
In- hospital complications, no./total no. (%)
Cardiogenic shock 22/110 (20.0) 127/1451 (8.8) <0.001
Death 16/112 (14.3) 46/1472 (3.1) <0.001
Hospitalization (days), 
median (IQR)
7 (4– 13) N=79 6 (3– 10) 
N=1006
0.021
5- year outcome, no./total no. (%)
MACCE 34/112 (30.4) 201/1472 (13.7) <0.001
Death 28/112 (25.0) 121/1472 (8.2) <0.001
ACE indicates angiotensin- converting- enzyme; ARB, angiotensin- 
receptor blocker; BNP, brain natriuretic peptide; COPD, chronic obstructive 
pulmonary disease; CRP, c- reactive protein; ECG, electrocardiogram; IQR, 
interquartile range; MACCE, major adverse cardiac and cerebrovascular 
events; QTc, QT interval corrected for heart rate; SD, standard deviation; 
TTS, takotsubo syndrome; ULN, upper limit of the normal; and WBC, white 
blood cell count.
*Including upper limits of the normal range for troponin T, high- sensitivity 
troponin T, and troponin I.
†Including upper limits of the normal range for brain natriuretic peptide and 
the N- terminal of prohormone brain natriuretic peptide.
‡Data obtained during catheterization or echocardiography; if both results 
were available data from catheterization were used.
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was significantly higher among patients with AF 
compared with those without AF (14.3% versus 
3.1%; P<0.001).
Long- Term Outcomes
Patients with AF had significantly worse long- term 
major adverse cardiac and cerebrovascular events 
and mortality rates compared with those without AF 
(Table  1). In addition, cumulative incidence curves 
showed a substantially higher mortality rate in pa-
tients with AF than in those without AF within the 
first 60 days (P<0.001; Figure 1). After 60 days and 
up to 5  years, a significant difference of mortality 
rates between patients with and without AF still ex-
isted (P=0.006; Figure 1). The 5- year mortality rate 
was substantially higher albeit not statistically signif-
icant in patients with AF and malignancy than in the 
counterparts without AF but with malignancy (35.3% 
versus 13.2%; P=0.19). A multivariable analysis 
demonstrated that AF on admission was indepen-
dently associated with long- term mortality (hazard 
ratio, 2.31; 95% CI, 1.50– 3.55; P<0.001; Figure  2). 
A comparison of AF subtypes revealed that 5- year 
mortality rates were 12.4%, 20.0%, 33.3% in pa-
tients with paroxysmal, persistent, or permanent AF, 
respectively.
Comparison of a History of AF Versus 
Newly Diagnosed AF
Of the patients with AF on admission, previous AF 
episodes were identified in 58% (48/83) of patients, 
whereas in the remaining 42% with AF the episode 
was considered the first in the patients’ history. Main 
patient characteristics between the 2 groups are sum-
marized in Table 2. No significant differences in clini-
cal characteristics were observed except for heart rate 
on admission (87.0±23.6 bpm versus 103.4±15.9 bpm; 
P=0.002). There were no significant differences on 
cardiovascular risk factors and coexisting medical 
conditions. Of the patients with preexisting AF, 57.1% 
were on oral anticoagulation therapy upon presenta-
tion, whereas 1 patient with newly diagnosed AF was 
prescribed such an agent before admission. Of note, 
acute intensive care measures including intra- aortic 
balloon pump, catecholamine use, invasive or nonin-
vasive ventilation, and cardiopulmonary resuscitation 
were required equally often in patients with preexist-
ing or newly diagnosed AF. Furthermore, in- hospital 
mortality rates were not statistically significant different 
between the 2 groups (18.8% versus 14.3%; P=0.59). 
Cumulative incidence curves showed that there were 
no significant differences on long- term major ad-
verse cardiac and cerebrovascular events (P=0.53) or 
Figure 1. Short- term and long- term mortality rates of patients with TTS with and without atrial 
fibrillation.
Cumulative incidence curves with a landmark set at 60 days show a higher mortality rate in patients with 
TTS with atrial fibrillation compared with patients with TTS without atrial fibrillation both in the short term 
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mortality (P=0.48) between patients with preexisting 
AF or newly diagnosed AF (Table 2).
DISCUSSION
In this of patients with TTS, we investigated the impact 
of AF on clinical outcomes and found the following: (1) 
patients with TTS with AF on surface ECG at admis-
sion had a more eventful in- hospital course and sig-
nificantly higher mortality rates compared with those 
without AF; (2) AF on admission was independently 
associated with a higher long- term mortality rate; (3) 
approximately one third of patients had no known his-
tory of AF before their TTS index event, suggesting 
that these patients may have developed new- onset AF; 
and finally (4) patients with TTS with preexisting AF and 
newly diagnosed AF had comparable in- hospital and 
long- term outcomes.
Among the 1584 patients with TTS, the prevalence 
of AF on admission was 7.1%. Previous studies re-
ported a prevalence ranging between 5% and 25% 
among patients with TTS.8– 10,15 In our study, fewer 
than a half of the patients (42%) who presented with 
AF during the index TTS event did not have a prior 
history of AF. This is higher than the results of Jesel 
et al, who reported an incidence of newly diagnosed 
AF or atrial flutter among patients with TTS of 24.8%.10 
Meanwhile, Stiermaier et al showed the total preva-
lence of AF in patients with TTS was 25%, of whom 
7.2% had new episodes of AF during their hospital 
stay.8 This indicates that in the majority of patients with 
TTS, new- onset AF is likely related to TTS. In this con-
text, it is of interest that patients with AF more com-
monly presented with apical ballooning and a lower 
LV ejection fraction, both conditions known to be as-
sociated with LV increased filling pressures and as a 
consequence increased left atrial pressures. Patients 
with TTS with AF also showed higher levels of inflam-
matory markers, including elevated C- reactive protein 
and WBC levels, than those without AF in the pres-
ent study. This is consistent with the study by Jesel 
et al, who also showed higher peak C- reactive protein 
and WBC levels among patients with TTS with newly 
diagnosed AF compared with those without atrial ar-
rhythmia.10 These findings suggest that inflammation 
plays a key role in AF during an acute TTS event. In 
this regard, recently published data on 56 patients 
with TTS has shown that increased serum interleukin 
(IL)- 6 and IL- 10 admission levels are associated with 
Figure 2. Multivariable Cox regression analysis of patients with TTS.
Multivariable Cox regression revealed that atrial fibrillation was independently associated with worse long- 
term mortality rates. Male sex, age>70 years, physical trigger, WBC>10×103 cells/µL, and LVEF<45% also 
emerged as independent predictors of worse long- term mortality rates in TTS. Errors bars represent 95% CI. 
Black rhombi indicate statistical significance; gray rhombi indicate no statistical significance. Bpm indicates 
beats per minute; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; 
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a higher risk of adverse events during follow- up.16 On 
the other hand, it has been suggested that activation 
of systemic inflammation may trigger atrial electrical 
remodeling, and it has been discussed whether direct 
cytokine- mediated effects on connexins are one of 
the underlying mechanisms. During acute or chronic 
inflammation, functional changes of atria might be 
documented by downregulating of cardiac connexins 
via increased IL- 6.17 Indeed, there is substantial evi-
dence demonstrating that TTS and AF might be as-
sociated with inflammation,18,19 although the precise 
mechanisms are unclear.
Acute AF is known to impair hemodynamics. 
Thus, it is of note that patients with TTS with AF on 
Table 2. Comparison between TTS Patients with 







Female sex, no./total 
no. (%)
44/48 (91.7) 30/35 (85.7) 0.48





Takotsubo Type, no./total no. (%)
Apical 42/48 (87.5) 32/35 (91.4) 0.7
Triggers, no./total no. (%)
Physical trigger 24/48 (50.0) 17/35 (48.6) 0.90
Emotional trigger 9/48 (18.8) 8/35 (22.9) 0.65
Symptoms on admission, no./total no. (%)
Chest pain 29/41 (70.7) 21/32 (65.6) 0.64
Syncope 1/46 (2.2) 2/32 (6.3) 0.57






















Inflammatory markers on admission, median (IQR)











ECG on admission, no./total no. (%)
ST- segment elevation 19/48 (39.6) 18/35 (51.4) 0.28
T- wave inversion 18/48 (37.5) 14/35 (40.0) 0.82








































Cardiovascular risk factors/history, no./
total no. (%)
Hypertension 41/47 (87.2) 31/34 (91.2) 0.73
Diabetes mellitus 14/47 (29.8) 7/33 (21.2) 0.39
Current smoking 7/45 (15.6) 5/31 (16.1) 0.95
Hypercholesterolemia 15/47 (31.9) 9/33 (27.3) 0.66









8/47 (17.0) 10/33 (30.3) 0.16
Cancer (total) 9/45 (20.0) 4/30 (13.3) 0.55
COPD or asthma 5/47 (10.6) 4/30 (13.3) 0.73
Medication on admission, no./total no. (%)
ACE inhibitor or ARB 21/41 (51.2) 13/27 (48.1) 0.80
Beta- blocker 20/41 (48.8) 14/27 (51.9) 0.80
Statin 10/41 (24.4) 5/27 (18.5) 0.57
Aspirin 21/41 (51.2) 12/26 (46.2) 0.69
Oral anticoagulants 24/42 (57.1) 1/32 (3.1) <0.001
Acute cardiac care, no./total no. (%)
Intra- aortic balloon 
pump
4/47 (8.5) 2/35 (5.7) >0.99
Cardiopulmonary 
resuscitation
10/47 (21.3) 6/35 (17.1) 0.64
Invasive or 
noninvasive ventilation
16/47 (34.0) 7/35 (20.0) 0.16
Catecholamine use 10/47 (21.3) 8/35 (22.9) 0.86
In- hospital complications, no./total no. (%)
Cardiogenic shock 13/46 (28.3) 5/35 (14.3) 0.13
Death 9/48 (18.8) 5/35 (14.3) 0.59
5- year outcome, no./total no. (%)
MACCE 17/48 (35.4) 11/35 (31.4) 0.53
Death 15/48 (31.3) 9/35 (25.7) 0.48
ACE indicates angiotensin- converting- enzyme; AF, atrial fibrillation; 
ARB, angiotensin- receptor blocker; BNP, brain natriuretic peptide; COPD, 
chronic obstructive pulmonary disease; CRP, c- reactive protein; ECG, 
electrocardiogram; IQR, interquartile range; MACCE, major adverse cardiac 
and cerebrovascular events; QTc, QT interval corrected for heart rate; SD, 
standard deviation; TTS, takotsubo syndrome; ULN, upper limit of the 
normal; and WBC white blood cell count.
*Including upper limits of the normal range for troponin T, high- sensitivity 
troponin T, and troponin I.
†Including upper limits of the normal range for brain natriuretic peptide and 
the N- terminal of prohormone brain natriuretic peptide.
‡Data obtained during catheterization or echocardiography; if both results 
were available data from catheterization were used.
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admission more often developed cardiogenic shock 
and required more commonly acute cardiac care 
measures including catecholamine administration 
and intra- aortic balloon pump insertion compared 
with those without AF. In addition, in- hospital mortal-
ity was significantly higher among patients with TTS 
with AF than among those without it. Our findings in 
our large TTS cohort are in line with observations in 
patients with ACS, in whom AF is associated with 
a higher rate of complications such as cardiogenic 
shock and life- threatening ventricular tachyarrhyth-
mias and poorer overall outcomes.20 The observed 
association between the presence of AF on ad-
mission and mortality in patients with TTS is likely 
related to the adverse hemodynamic effects of AF, 
such as loss of atrial contraction and the resultant 
loss of atrioventricular synchronicity, rhythm irregu-
larity, and rapid ventricular rates. All of these aspects 
contribute further to the reduced LV ejection fraction 
and cardiac output. In addition, there is evidence 
demonstrating that TTS and AF might be associated 
with inflammation.18 Interestingly, patients with TTS 
with AF had a greater degree of inflammatory mark-
ers (C- reactive protein and WBC) than those without 
AF in the present study. Therefore, it is conceivable 
that a strong inflammatory response might lead to 
a more eventful outcome in patients with TTS with 
AF. Furthermore, AF is known to increase the risk of 
cardioembolic events in patients with TTS.21 Such 
risk might be more pronounced in patients with TTS 
given the severe hypokinesia/akinesia of the ventric-
ular wall in apical ballooning during the acute phase 
of the disease.
Besides ACS and TTS reported here, AF has been 
reported as a predictor of poor long- term prognosis in 
patients with other cardiac conditions such as dilated 
cardiomyopathy and congenital heart disease.22,23 
Furthermore, in patients with chronic coronary syn-
dromes, AF has been associated with significantly 
higher rates of thromboembolic stroke, heart failure, and 
long- term mortality, regardless of the time of AF onset. 
Interestingly, although global LV ejection fraction is nor-
malized within a few weeks in TTS, we demonstrated 
by landmark analysis that the long- term mortality rate 
was still significantly higher in the AF group than in the 
non- AF group after excluding the strong influence of the 
acute phase. In addition, AF emerged as an indepen-
dent predictor of long- term mortality in TTS.
We also demonstrated that mortality differs de-
pending on the AF subtype, that is, patients with par-
oxysmal AF had the lowest mortality rates. Similarly, 
Link et al showed that paroxysmal AF is associated 
with a more favorable outcome than persistent or per-
manent AF.24 Thus, all patients with TTS with AF on 
admission need to be managed appropriately accord-
ing to the established guidelines for AF.25
The prevalence of AF in TTS is comparable with that 
of AF in ACS,26 which implies they may share a common 
pathophysiological mechanism. Indeed, heart failure, 
regardless of etiology, is associated with sympathetic 
activation that can be detrimental for the atrial substrate. 
This activation likely results from the neuro- hormonal 
system and catecholaminergic activation as well as me-
chanical stretching of cardiomyocytes and ionic channel 
dysfunction. During ventricular overload, cell membrane 
stretching may activate certain ion channels in the car-
diomyocytes and alter their electrical activity, resulting 
in mechano- electrical feedback that increases the risk 
of arrhythmia.27,28 Also, human cardiomyocytes from 
induced pluripotent stem cells modeling TTS show in-
creased late sodium current and decreased transient 
outward current.29 Such an elevated late sodium current 
is observed in both TTS and ACS and may be triggered 
by a prolongation of repolarization.29,30 However, further 
investigation into the underlying pathophysiological cas-
cades of TTS and ACS is required.
Limitations
Because the InterTAK Registry is an in part retrospec-
tive registry, recall bias cannot be fully excluded. The 
definition of the presence of AF was based on ECG 
on admission, and the duration of AF was not as-
sessed. The power to account for confounding factors 
is limited, and some residual selection bias might be 
present. Finally, we cannot rule out that AF was the 
primary cause of transient tachycardia- induced car-
diomyopathy rather than an incidental correlate of TTS.
CONCLUSIONS
Patients with TTS with AF on surface ECG on admission 
had a more eventful in- hospital course and significantly 
higher mortality rates than patients with TTS without 
AF. Furthermore, AF was statistically significantly as-
sociated with a higher long- term mortality. Although 
some patients with AF on admission had no known 
prior history of AF, they had comparable in- hospital 
and long- term outcomes compared with those with 
preexisting AF. Thus, the presence of AF on admission 
should alert clinicians to the prognostic implications of 
this rhythm. Adequate AF management as part of the 
overall TTS treatment strategy may improve outcomes 
of patients with TTS with AF.
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Figure S1. Description of triggering factors in takotsubo syndrome patients with and 
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